Liu Ming, He Wenxin, Yang Jie, Jiang Gening
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
J Thorac Dis. 2016 Jun;8(6):1197-204. doi: 10.21037/jtd.2016.04.46.
Synchronous multiple primary lung cancers (SMPLC) become more common in clinical practice. To identify factors attributed to SMPLC treatment outcomes, we have reviewed our experiences with surgical resections of SMPLC and analyzed the treatment outcomes in this paper.
We retrospectively analyzed clinical characteristics and treatment outcomes of patients who have been diagnosed as SMPLC and underwent surgical resection between 1990 and 2010. Based on EGFR and KRAS mutations, we identified 27 cases as SMPLC out of 50 cases, which were difficult to distinguish primary lung cancers from metastases. A total of 265 tumors from 122 patients were studied.
The 5-year survival rate for all patients was 40.5%. There was a significant difference in the 5-year survival between smokers and never-smokers (30.8% vs. 55.6%, P=0.011). Survival rate was also different between patients with same tumor histology and those with different tumor histology (46.9% vs. 24.8%, P=0.036). In addition, Solid nodule and pneumonectomy were associated with the worse survival (P=0.026, P=0.030). Multivariable analysis identified smoking status, stage, lymph node metastasis and pneumonectomy as significant independent predictive factors for overall survival.
Surgical treatment is a safe approach for patients with SMPLC; pneumonectomy should be avoided as far as possible given the poor prognosis. Mutational status of EGFR and KRAS may be advocated as a diagnostic criteria of synchronous lung cancer rather metastasis mainly in case of adenocarcinoma histology.
同步性多原发性肺癌(SMPLC)在临床实践中愈发常见。为确定影响SMPLC治疗效果的因素,我们回顾了SMPLC手术切除的经验,并分析了本文中的治疗结果。
我们回顾性分析了1990年至2010年间被诊断为SMPLC并接受手术切除的患者的临床特征和治疗结果。基于表皮生长因子受体(EGFR)和 Kirsten 大鼠肉瘤病毒癌基因(KRAS)突变,我们从50例难以区分原发性肺癌与转移瘤的病例中确定了27例为SMPLC。共研究了122例患者的265个肿瘤。
所有患者的5年生存率为40.5%。吸烟者与从不吸烟者的5年生存率存在显著差异(30.8%对55.6%,P = 0.011)。相同肿瘤组织学类型与不同肿瘤组织学类型患者的生存率也有所不同(46.9%对24.8%,P = 0.036)。此外,实性结节和肺叶切除术与较差的生存率相关(P = 0.026,P = 0.030)。多变量分析确定吸烟状态、分期、淋巴结转移和肺叶切除术是总生存的显著独立预测因素。
手术治疗对SMPLC患者是一种安全的方法;鉴于预后较差,应尽可能避免肺叶切除术。对于同步性肺癌而非主要是转移瘤的诊断标准,在腺癌组织学类型的情况下,可提倡EGFR和KRAS的突变状态。